Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Blood (2023) 142 (Supplement 1): 1513.

https://doi.org/10.1182/blood-2023-185045

Published: 2023

Journal Articles

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

Patrizio Panelli, Elisabetta De Santis, Mattia Colucci, Francesco Tamiro, Francesca Sansico, Mattia Miroballo, Emanuele Murgo, Costanzo Padovano, Sam Gusscott, Michele Ciavarella, Elizabeth A. Chavez, Fabrizio Bianchi, Giovanni Rossi, Angelo M. Carella, Christian Steidl, Andrew P. Weng, Vincenzo Giambra

Blood (2023) 141 (13): 1597–1609.

https://doi.org/10.1182/blood.2022017079

Published: 2023

Includes: Supplemental data

Journal Articles

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Blood (2018) 132 (Supplement 1): 4642.

https://doi.org/10.1182/blood-2018-99-114486

Published: 2018

Journal Articles

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Blood (2017) 130 (Supplement 1): 519.

https://doi.org/10.1182/blood.V130.Suppl_1.519.519

Published: 2017

Journal Articles

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

Blood (2016) 128 (22): 470.

https://doi.org/10.1182/blood.V128.22.470.470

Published: 2016

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Francesco Zaja, Stefano Volpetti, Annalisa Chiappella, MD, Flavia Salvi, MD, Angelo M. Carella, Adalberto Ibatici, Pier Paolo Piccaluga, Stefano A. Pileri, Davide Rossi, MD PhD, Pier Luigi Zinzani, Caterina Patti, Umberto Vitolo, Alfonso D'Arco, Alessandra Tucci, Silvia Franceschetti, Andrea Evangelista, Valentina Lenti, Renato Fanin, Alessandro Levis

Blood (2014) 124 (21): 1755.

https://doi.org/10.1182/blood.V124.21.1755.1755

Published: 2014

Journal Articles

Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease

A. M. Carella, MD, G. Beltrami, MD, G. Pica, MD, C. Ghiggi, MD, D. Lovera, MD, G. Cirmena, A. Garuti

Blood (2012) 120 (21): 3777.

https://doi.org/10.1182/blood.V120.21.3777.3777

Published: 2012

Journal Articles

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

Carlo Marani, MD, Raffaella Grasso, PhD, Nicoletta Colombo, Marino Clavio, MD, Fabio Guolo, MD, Annalisa Kunkl, Livia Giannoni, MD, Giuseppina Fugazza, PhD, Roberto Bruzzone, Mario Sessarego, MD, A. M. Carella, MD, Marco Gobbi, MD, Maurizio Miglino, PhD

Blood (2012) 120 (21): 2535.

https://doi.org/10.1182/blood.V120.21.2535.2535

Published: 2012

Journal Articles

A Phase I Study of Hypofractionated Tailored Total Marrow or Total Lymphoid Irradiation with Helical Tomotherapy Plus Chemotherapy As a Conditioning Regimen for Autologous Stem Cell Transplantation

G. Pica, S. Vagge, G. Beltrami, S. Nati, G. Catania, R. Corvò, A. M. Carella, MD

Blood (2011) 118 (21): 4523.

https://doi.org/10.1182/blood.V118.21.4523.4523

Published: 2011

Journal Articles

GeneXpert Essay for BCR-ABL Compared to RT-PCR for Clinical Management of CML

G. Pica, G. Catania, F. Castelli, C Repetto, A. M. Carella, MD, M. Mussap

Blood (2011) 118 (21): 4416.

https://doi.org/10.1182/blood.V118.21.4416.4416

Published: 2011

Journal Articles

Clarithromycin Targeting Autophagy Potentiates Tyrosine Kinase Inhibitor-Induced Cell Death in Resistant Chronic Myeloid Leukemia (CML) Patients

A. M. Carella, MD, Gioacchino Catania, MD, G. Beltrami, G. Pica

Blood (2011) 118 (21): 4450.

https://doi.org/10.1182/blood.V118.21.4450.4450

Published: 2011

Journal Articles

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

G. Pica, S. Nati, Umberto Vitolo, MD, Sara Galimberti, Pier Luigi Zinzani, MD, PhD, Nicola Cascavilla, Mario Petrini, MD, A. M. Carella, MD

Blood (2011) 118 (21): 100.

https://doi.org/10.1182/blood.V118.21.100.100

Published: 2011

Journal Articles

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Domenico Russo, Giuliana Alimena, Chiara Colombi, Massimo Breccia, Simona Soverini, Ilaria Iacobucci, PhD, Federica Cattina, MD, Giovanni Martinelli, MD, Nicoletta Testoni, Anna Marina Liberati, Viviana Appolloni, Mario Tiribelli, Renato Fanin, Felicetto Ferrara, MD, Mario Annunziata, MD, Elena Trabacchi, Daniele Vallisa, MD, Antonio De Vivo, Fausto Castagnetti, Miriam Fogli, Sandra Durante, Francesco Di Raimondo, MD, Fabio Stagno, A. M. Carella, G. Pica, Alessandra Iurlo, M.D., Tommaso Radice, Patrizia Pregno, MD, Umberto Vitolo, MD, Elisabetta Abruzzese, Paolo de Fabritiis, Maurizio Longinotti, MD, Simonetta Pardini, Caterina Musolino, MD, Sabina Russo, Marco Gobbi, MD, Ivana Pierri, Gianluca Gaidano, Monia Lunghi, M.D., Giuseppe Visani, Sara Barulli, Mario Cazzola, Serena Merante, Cristina Skert, MD, Michele Malagola, Gianantonio Rosti, MD, Michele Baccarani, MD

Blood (2011) 118 (21): 786.

https://doi.org/10.1182/blood.V118.21.786.786

Published: 2011

Journal Articles

Sustained Complete Molecular Response (CMR) with Interferon-alpha Maintenance After Induction with Imatinib In Chronic Myeloid Leukemia (CML) Patients.

A. M. Carella, G. Catania, G. Pica and G. Beltrami

Blood (2010) 116 (21): 4486.

https://doi.org/10.1182/blood.V116.21.4486.4486

Published: 2010

Journal Articles

ABL Mutations In Early Chronic Phase Chronic Myeloid Leukemia (CP-CML) Are Associated with a Greater Likelihood of Progression and Shorter Survival

A. M. Carella, A. Garuti, G. Cirmena, G. Catania, G. Pica, G. Beltrami, F. Patrone

Blood (2010) 116 (21): 4458.

https://doi.org/10.1182/blood.V116.21.4458.4458

Published: 2010

Journal Articles

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Blood (2010) 116 (17): 3171–3179.

https://doi.org/10.1182/blood-2010-03-276196

Published: 2010

Journal Articles

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Blood (2010) 115 (18): 3671–3677.

https://doi.org/10.1182/blood-2009-12-253856

Published: 2010

Journal Articles

Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph + ALL) Treated at Diagnosis with Imatinib Followed by 2 nd Line TKI (Imatinib or Dasatinib) and Stem Cell Transplantation.

A. M. Carella, G. Catania, G. Pica, G. Beltrami, S. Nati, R. Vimercati, A. Congiu, E. Rossi, M. Spriano

Blood (2009) 114 (22): 4109.

https://doi.org/10.1182/blood.V114.22.4109.4109

Published: 2009

Journal Articles

90 y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group

A. M. Carella, S. Nati, G. Fraternali Orcioni, M. Petrini, S. Galimberti, U. Vitolo, N. Cascavilla, P.L. Zinzani

Blood (2008) 112 (11): 3061.

https://doi.org/10.1182/blood.V112.11.3061.3061

Published: 2008

NARROW

Phase II Study on Venetoclax (Ven) Plus Decitabine (Dec) (Ven-Dec) for Elderly (≥60 <75years) Patients with Newly Diagnosed High-Intermediate Risk Acute Myeloid Leukemia (AML) Elegible for Allogeneic Stem Cell Transplantation: Final Report of Ven DEC GITMO Study

Noncanonical β-catenin interactions promote leukemia-initiating activity in early T-cell acute lymphoblastic leukemia

High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt

Prophylaxis with ATLG Significantly Improves Chronic Graft-Versus-Host Disease / Relapse-Free Survival and Quality of Life after a Myeloablative HLA Identical Sibling Transplant for Acute Leukemia Patients in Complete Remission. Long-Term Follow-up of the Randomized ATG Familystudy

Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA)

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL)

Clarithromycin Enhances tyrosine Kinase Inhibitor – Induced Cell Death by Inhibition of Late Stage Autophagy in Patients with Chronic Myeloid Leukemia At Diagnosis or with Resistant Stage of Disease

Minimal Residual Disease After the First Cycle of Chemotherapy in Acute Myeloid Leukemia: A Comparative Study of WT1 RQ-PCR and 4-Color Flow Cytometry.

A Phase I Study of Hypofractionated Tailored Total Marrow or Total Lymphoid Irradiation with Helical Tomotherapy Plus Chemotherapy As a Conditioning Regimen for Autologous Stem Cell Transplantation

GeneXpert Essay for BCR-ABL Compared to RT-PCR for Clinical Management of CML

Clarithromycin Targeting Autophagy Potentiates Tyrosine Kinase Inhibitor-Induced Cell Death in Resistant Chronic Myeloid Leukemia (CML) Patients

Safety and Efficacy of 90Y Ibritumomab Tiuxetan (Zevalin®) for Untreated FollicularNon-Hodgkin's Lymphoma (FL) Patients, An Italian Cooperative Study

Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509

Sustained Complete Molecular Response (CMR) with Interferon-alpha Maintenance After Induction with Imatinib In Chronic Myeloid Leukemia (CML) Patients.

ABL Mutations In Early Chronic Phase Chronic Myeloid Leukemia (CP-CML) Are Associated with a Greater Likelihood of Progression and Shorter Survival

Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph + ALL) Treated at Diagnosis with Imatinib Followed by 2 nd Line TKI (Imatinib or Dasatinib) and Stem Cell Transplantation.

90 y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only